Medizinische Klinik und Poliklinik II, Innere Medizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
EPMA J. 2011 Mar;2(1):119-30. doi: 10.1007/s13167-011-0068-z. Epub 2011 Mar 5.
Cardiac diseases are the leading cause of death and reach epidemic proportions with aging. Advanced heart disease results from an abrupt or progressive loss of contractile cardiomyocytes. Following percutaneous coronary intervention and revascularization regenerative medicine aims at effectively repair damaged tissue and replacement of lost cardiomyocytes. However, mixed results were obtained from trials using bone marrow-derived stem cells. Benefits were rather attributed to paracrine effects leading to inhibition or reverse of negative remodeling processes than to regeneration of viable cardiomyocytes. Thus the aim of regenerative medicine, in particular stem cell research, to generate viable cardiac muscle has so far not been achieved in humans, reflecting our incomplete understanding of underlying biological mechanisms. Moreover, there is growing evidence that substantial person-to-person differences in the outcome of stem cell therapy exists. We here review our present knowledge in evolving stem cell based cardiovascular medicine and highlight personalized aspects of stem cell interventions.
心脏疾病是导致死亡的主要原因,随着人口老龄化,其发病率呈上升趋势。晚期心脏病是由收缩型心肌细胞的突然或渐进性丧失引起的。经皮冠状动脉介入治疗和血运重建后,再生医学旨在有效修复受损组织和替代丢失的心肌细胞。然而,使用骨髓来源的干细胞进行的试验结果喜忧参半。其益处归因于旁分泌作用,从而抑制或逆转负性重构过程,而不是生成有活力的心肌细胞。因此,再生医学(特别是干细胞研究)产生有活力的心肌的目标在人类中尚未实现,这反映了我们对潜在生物学机制的理解尚不完全。此外,越来越多的证据表明,干细胞治疗的结果在人与人之间存在很大差异。在这里,我们回顾了目前基于干细胞的心血管医学的知识,并强调了干细胞干预的个性化方面。